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Extensive evidence implicates dysfunction in serotonin (5-HT) signaling in the etiology
of major depressive disorder (MDD). Dorsal raphe nucleus (DR) is a major source of
serotonin in the brain, and previous studies have reported within it alterations in 5-HT-
related gene expression, protein levels, receptor binding, and morphological organization
in mood disorders. In the present study, we utilized in situ hybridization-guided laser cap-
ture microdissection to harvest tissue samples from the middle-caudal subregion of the
human DR post-mortem from MDD patients and from psychiatrically normal comparison
subjects. Extracted RNA was prepared for gene expression profiling, and subsequent con-
firmation of select targets with quantitative real-time PCR. Our data indicate expression
changes in functional gene families that regulate: (1) cellular stress and energy balance, (2)
intracellular signaling and transcriptional regulation, and (3) cell proliferation and connectiv-
ity. The greatest changes in expression were observed among transcriptional regulators,
including downregulation in the expression of TOB1, EGR1, and NR4A2 and their down-
stream targets. Previous studies have implicated these gene products in the regulation
of functional domains impacted by MDD, including cognitive function, affective regulation,
and emotional memory formation. These observations indicate altered function of several
transcriptional regulators and their downstream targets, which may lead to the dysregu-
lation of multiple cellular functions that contribute to the pathophysiology of MDD. Future
studies will require single cell analyses in the DR to determine potential impact of these
changes on its cellular functions and related circuits.
Keywords: serotonin, postmortem, gene expression, microarray, real-time PCR, laser capture microdissection,
depression
INTRODUCTION
Major depressive disorder (MDD) is among the most debilitating
neuropsychiatric illnesses. With an estimated lifetime prevalence
of 16%, MDD is characterized by a high burden of morbid-
ity caused by co-occurrence of physical ailments together with
a high level of mortality due to suicide (Carney et al., 1993; Frank
and Thase, 1999; Penninx et al., 2001; Kessler et al., 2003; Brown
et al., 2004; Taylor and MacQueen, 2006). Despite increased pub-
lic awareness and enormous research efforts, the etiology and
pathophysiology of MDD remain poorly understood, and few
fully effective treatments are available. The most compelling the-
ory of the etiology of MDD has been the monoaminergic the-
ory of depression, which posits a deficit in the concentration of
monoaminergic neurotransmitters such as serotonin (5-HT) in
the brains of depressed patients (Bunney and Davis, 1965; Schild-
kraut, 1965; Coppen, 1968; Lapin and Oxenkrug, 1969; Hirschfeld,
2000; Leonard, 2000). Consistent with this theory, first-line treat-
ments for MDD include medications that increase absolute con-
centrations of monoaminergic neurotransmitters at the synapse,
such as selective 5-HT reuptake inhibitors (SSRIs) or tricyclic
antidepressants (Leonard, 2000; Blier, 2001). The theory also
involves an assumption that, conversely, depletion of monoamin-
ergic transmitters can induce a depressive state (Goodwin and
Bunney, 1971; Neumeister, 2003).
The single largest source of serotonergic innervation of the
forebrain is the dorsal raphe nucleus (DR; Azmitia, 1999). Via its
dense innervation of forebrain limbic and cortical regions, the DR
regulates affect, cognition, reward, and homeostasis, all of which
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are disturbed in MDD (Lowry et al., 2008). Previous studies have
documented extensive alterations in the serotonergic system in the
depressed brain, including alterations in 5-HT receptor binding,
gene expression, protein levels, and reuptake transporter function
in both the forebrain and the brainstem (Arango et al., 1996a,b,
2001, 2002; Klimek et al., 1997; Underwood et al., 1999; Zhu
et al., 1999; Ordway et al., 2003; Boldrini et al., 2005, 2008; Bach-
Mizrachi et al., 2006, 2008; Matthews and Harrison, 2012); these
data suggest a disruption of 5-HT circuits both at the level of the
cell body as well as the terminal. Consistent with this notion, a
number of studies have documented gene expression alterations
in the DR in depression (Arango et al., 2001; Boldrini et al., 2005;
Bach-Mizrachi et al., 2006, 2008; Goswami et al., 2010).
All of these previous studies were hypothesis driven and focused
solely on expression of genes that directly regulate 5-HT neuro-
transmission or 5-HT receptor signaling. Because MDD is a mul-
tifactorial and is likely a polygenic disorder, a dysregulated 5-HT
pharmacologic state alone cannot account for all DR abnormali-
ties. Therefore, the current study utilized an unbiased microarray-
based approach to identify novel expression alterations of genes in
the DR in MDD in postmortem human tissue. Our data indicate
alterations in the expression of multiple transcriptional regulators
that have the potential to impact diverse cellular functions within
the DR and contribute to the etiology of MDD.
MATERIALS AND METHODS
SUBJECTS
Acquisition of postmortem human brain samples were conducted
at the University of California at Irvine Brain Bank. Tissue process-
ing, and procedures for microarray experiments have been previ-
ously described (Evans et al., 2004; Tomita et al., 2004; Choudary
et al., 2005; Bernard et al., 2011). Brainstem tissue blocks were
collected from depressed subjects (n= 13; antemortem diagnoses
of MDD) and from non-psychiatric controls (C; n= 8; Table 1).
Because extensive agonal stress and low tissue pH dramatically
impact profiles of gene expression in the brain (Li et al., 2004;
Tomita et al., 2004; Atz et al., 2007), blocks were collected only
from subjects that experienced sudden deaths (agonal factor score
of 0), and only samples from brains with pH> 6.6 were included
in further processing (Table 1).
TISSUE PROCESSING
Tissue blocks were sectioned on a cryostat in a coronal plane to a
thickness of 10µm and immediately thaw mounted onto Super-
Frost glass slides (Fisher Scientific,Pittsburgh,PA,USA). Each slide
contained one section, and slides were stored at−80˚C. Every 50th
slide was then processed for radioactive in situ hybridization (ISH)
to detect the distribution of serotonin transporter (SERT) mRNA
as previously described (Lopez-Figueroa et al., 2004; Bernard et al.,
2009). Specificity of the ISH probe was validated using sense
controls and tissue pretreatment with RNase (data not shown).
Processed tissue sections were apposed to radiosensitive film (Bio-
Max MR film, Kodak1) for 7 days to delineate the anatomical
boundaries of the DR.
1http://www.kodak.com
Slides processed for ISH were then stained with a modified
Klüver–Barrera method, which included staining with cresyl vio-
let and luxol fast blue to identify neurons and fibers of passage.
Distribution of SERT ISH signal was used in combination with
histologically stained slides to delineate the regions of interest
and to facilitate anatomical alignment of the specimens. This
approach ensured that we sampled from the same antero-posterior
subregion of DR common among all subjects in our cohort.
SERT autoradiograms and histologically stained slides were
digitized and used to guide laser capture microdissection (LCM)
on adjacent unstained tissue sections. It was important to use
unstained tissue for LCM so as to preserve RNA integrity for the
downstream gene expression assays. At the same time, use of the
histologically and neurochemically stained adjacent guide sections
allowed precise anatomical delineation of DR and related brain-
stem nuclei (Bernard et al., 2009, 2011). Samples were harvested
from the middle-caudal DR, with bilateral collection from three
consecutive tissue sections at three levels separated by 500µm
(total of nine DR nuclei). Position of anatomical landmarks,
including the fourth ventricle and medial longitudinal fascicu-
lus, from histochemically stained images, and SERT ISH signal
were visually projected onto sections used for LCM. Regions in
unstained sections that corresponded to boundaries of the DR
were then microdissected under a 4× objective using CapSure
macrocaps (Applied Biosystems) as previously described (Bernard
et al., 2009). We have previously validated neuroanatomical
precision of this approach (Bernard et al., 2009).
RNA ISOLATION AND AMPLIFICATION
RNA extraction and isolation were performed with the use of the
PicoPure RNA Isolation Kit (Molecular Devices, Sunnyvale, CA,
USA) according to manufacturer’s instructions, including DNase
treatment. For each nucleus, RNA extracts from the three LCM
caps from the same subject were combined before purification.
RNA quantity and quality were evaluated using the 2100 BioAn-
alyzer (Agilent Technologies, Palo Alto, CA, USA). RNA quality
and its suitability for downstream gene expression analyses were
determined from BioAnalyzer electropherograms according to the
method of Schoor et al. (2003). Accordingly, extracted RNA sam-
ples were considered acceptable for downstream gene expression
analyses if they met the following criteria: (1) <65% of the total
area under the electropherogram curve was between the end of
the marker peak and the beginning of the 18S rRNA peak, and (2)
>4% of the total area was under the 28S rRNA peak (Schoor et al.,
2003; Bernard et al., 2009). All of our samples met these exclusion
criteria and were included in further analyses and processing.
RNA samples were subjected to two rounds of amplification
(RiboAmp OA RNA Kit, Molecular Devices) and subsequent
biotin labeling (Perkin Elmer, Waltham, MA, USA) according
to manufacturers’ instructions. A portion of the second strand
cDNA synthesis reaction product (i.e., amplified double-stranded
cDNA), generated from RNA following in vitro transcription at
the end of the first round of amplification was set aside for quan-
titative real-time PCR (qPCR; see below). After two amplification
rounds, 15µg of biotinylated amplified RNA from each DR sam-
ple were then hybridized to HG-U133 Plus 2.0 arrays (Affymetrix,
Santa Clara, CA, USA) per manufacturer’s instructions.
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Table 1 | Demographic and clinical characteristics of subjects included in the study.
Diagnosis Subject Race Age Sex PMI (hours) Agonal factor Brain PH Cause of death SSRI at time of death
Control 2169 Caucasian 18 M 22 0 6.97 Accident No
Control 2292 Caucasian 55 M 15 0 6.89 Sudden med. cond. No
Control 2805 Caucasian 45 M 21 0 6.86 Sudden med. cond. No
Control 3228 Pacific Islander 39 M 18.15 0 6.81 Sudden med. cond. No
Control 3516 Caucasian 41 M 22.5 0 7.01 Sudden med. cond. No
Control 3519 African American 65 M 13.5 0 6.88 Sudden med. cond. No
Control 3520 Caucasian 74 F 18.5 0 7.21 Sudden med. cond. No
Control 3588 Caucasian 56 M 24.5 0 6.98 Sudden med. cond. No
MDD 2208 Caucasian 72 F 21 0 7.13 Suicide No
MDD 2267 Caucasian 19 M 18 0 7.11 Suicide No
MDD 3064 Caucasian 46 M 27 0 6.91 Sudden med. cond. No
MDD 3169 Caucasian 35 M 24.75 0 7.04 Accident No
MDD 3365 Caucasian 47 M 29 0 7.25 Suicide No
MDD 3426 Caucasian 63 M 28.5 0 7.17 Sudden med. cond. No
MDD 3031 Caucasian 49 M 27 0 7.19 Suicide No
MDD 3398 Caucasian 80 F 15 0 6.68 Sudden med. cond. No
MDD 2315 Caucasian 58 M 24 0 6.93 Suicide Yes
MDD 2944 Caucasian 52 M 16 0 6.82 Sudden med. cond. Yes
MDD 3071 Caucasian 49 M 31 0 7 Unknown Yes
MDD 3168 Caucasian 39 M 27.5 0 6.79 Suicide Yes
MDD 3481 Caucasian 66 M 32 0 7.05 Sudden med. cond. Yes
All subjects in the cohort were well matched for age, gender, race, post-mortem interval, agonal factor, and pH. F, female; M, male; MDD, major depressive disorder;
cond., condition; PMI, post-mortem interval; SSRI, selective serotonin reuptake inhibitor.
GENE EXPRESSION MICROARRAYS
Affymetrix CEL files were analyzed with the use of the Robust
Multi-Chip Average (RMA) and the Affymetrix Microarray Suite
5 calls (MAS5CALLS) algorithm. Affymetrix chip description files
were replaced by custom probe set mapping files2 that indepen-
dently reassigned all Affymetrix probe sets to an updated UniGene
cluster (Dai et al., 2005). Log2-based microarray intensity values
were used for statistical analyses.
Gene expression differences were evaluated by using Student’s
t -tests and were considered to be significant if: (1) the p-values
were≤0.05, (2) expression was detected in≥50% of arrays in C or
MDD groups according to the MAS5CALLS algorithm, and (3) a
gene’s log2 intensity value was≥4.0 according to RMA algorithm.
Fold change differences were calculated from group averages of
microarray intensity values. Pearson’s correlations (two-tailed p-
values) between microarray and qPCR results were computed
using MS Excel 2010.
QUANTITATIVE REAL-TIME PCR
We used SYBR Green chemistry for qPCR validation of microarray
results. Genomic DNA and mRNA sequences were downloaded
from NCBI Entrez Gene3, and Primer3 software (Rozen and
Skaletsky, 2000) was used to design primers to: (1) anneal within
500 bp of the 3′ end, (2) generate a single amplicon 75–150 bp in
size, and (3) amplify all splice variants for the gene of interest. For
each amplicon, predicted secondary structure was minimized with
2http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/
genomic_curated_CDF.asp
3http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD= search&DB= gene
the use of DNA Mfold (Zuker, 20034). Primer sequences are listed
in Table 2. Primer performance was validated via serial dilutions
and amplification efficiency testing by using human genomic DNA
and/or amplified cDNA from human brainstem sections [source
of input DNA did not impact amplification efficiency (data not
shown)].
Reactions were carried out in 96-well PCR plates
(Bio-Rad, Hercules, CA, USA). Each well contained 5µl of ampli-
fied double-stranded cDNA (50 pg/µl), which was set aside after
the second strand cDNA synthesis performed following in vitro
transcription at the end of first round of mRNA amplification (as
described above). Concentration of amplified cDNA was quan-
tified for each sample by using Quant-iT PicoGreen dsDNA Kit
(Invitrogen, Carlsbad, CA, USA) according to manufacturer’s
instructions. Each qPCR well also contained 5µl of forward and
reverse strand primers (final concentration 500 nM) and 10µl of
iQ SYBR Green Supermix (Bio-Rad).
A Bio-Rad iCycler (Bio-Rad) was utilized for amplifications,
which were performed by using a touchdown PCR approach: dena-
ture at 95˚C for 1 min 45 s, followed by ten cycles of (1) denaturing
at 95˚C for 15 s, (2) annealing at 65–60˚C for 15 s, and (3) extension
at 72˚C for 15 s. Annealing temperature was decreased at each step
of the cycle by 0.5˚C from a maximum of 65˚C to the final tem-
perature of 60˚C. This was followed by 45 cycles of (1) denaturing
at 95˚C for 15 s, (2) annealing at 60˚C for 15 s, and (3) extension
at 72˚C for 15 s. Fluorescence was quantified after the extension
step by using a FAM-490 or SYBR-488 detection protocol at a peak
4http://www.bioinfo.rpi.edu/applications/mfold/
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Table 2 | Primers used for qPCR.
Gene name Gene
symbol
Accession
number
Primers (forward, reverse) Tm (˚C) Product
size (bp)
Transducer of ERBB2, 1 TOB1 NM_005749 TTTTCATTTGCCAACCAAGC 60.98 115
AAAATCAGCCATGTCCTTGC 60.08
Nuclear receptor subfamily 4, group A, member 2 NR4A2 NM_173173 ACACCGTCCAACATTCCTTG 60.81 113
TGCATGCAAGTTTTGTTTAGC 59.02
CD69 molecule CD69 NM_001781 AGACAGGTCCTTTTCGATGG 59.14 147
TGCCACATCACATATTGCAC 58.95
Early growth response 1 EGR1 NM_001964 TAGGCGGCGATTTTTGTATG 60.95 138
TATCCCATGGGCAATAAAGC 59.76
TCDD-inducible poly(ADP-ribose) polymerase TIPARP NM_015508 TTCCTCAGTTCAGAGAGGTAGC 57.82 139
AAACATTACCAGGAGAGCTTGG 59.65
Protein phosphatase 1, regulatory (inhibitor) subunit 3C PPP1R3C NM_003053 TGTGCACAACCATTGAGAGG 60.72 75
TACTTTTCCACCATGGCACA 59.96
Adrenomedullin ADM NM_001124 GTGAATGTCTCAGCGAGGTG 59.42 110
TCGGTGTTTCCTTCTTCCAC 60.09
CXCR7 chemokine (C-X-C motif) receptor 7 CXCR7 NM_020311 ATATTGTTTGGGAGGCATAGTG 58.03 75
CAAAACTGAAGTCACGCTAACC 58.95
Nuclear receptor subfamily 4, group A, member 3 NR4A3 NM_006981 TGTGAACATGCCTTCTGTGG 60.72 120
GCAATGCTGTTAGAGGAGCAG 60.17
Solute carrier family 19 (thiamine transporter), member 2 SLC19A2 NM_006996 TTGTGGCATACAACCTGAGC 59.72 97
TGCACATTGAGTTCAGCATTC 59.86
Eukaryotic translation elongation factor 1 alpha 1 EEF1A1 NM_001402 TTGACATGCAAGGAAGCAAG 59.99 138
GTGCTCAAGCCACAGTTGTC 59.47
bp, base pairs; Tm, melting temperature.
excitation wavelength of 490 nm and peak emission wavelength of
530 nm.
After amplification was completed, PCR products were dena-
tured by sequential increases in temperature from 72 to 95˚C in
0.5˚C increments. At each step the temperature was held con-
stant for 10 s, during which time fluorescence was quantified. The
presence of specific amplification products was confirmed by the
presence of a single peak on one of these melting curves, which
were plotted as the negative derivative of fluorescence as a func-
tion of temperature. No template controls, in which DNA was
replaced with distilled H2O, did not yield fluorescent signals (e.g.,
no amplification products).
All samples were amplified in triplicate, and an average cycle
threshold (Ct) was calculated for each sample. Replicates that were
≥1 Ct away from the mean Ct were excluded; the mean Ct included
only the remaining duplicates. Because input amount of ampli-
fied cDNA was equivalent across all samples, raw Ct values were
inversely proportional to the levels of gene expression (Libus and
Storchova, 2006). We chose this approach instead of normaliza-
tion to housekeeping genes because of the potential for differential
expression of such reference transcripts in disease versus control
samples (Dheda et al., 2005; Wong and Medrano, 2005). A similar
approach has recently been validated in which standardized DNA
input amounts for qPCR were used (Bernard et al., 2009, 2011).
The following formula was used to calculate relative fold changes:
2−(Cta-Ctb) where Cta is cycle threshold in the MDD group and
Ctb is cycle threshold in the C group.
RESULTS
ORGANIZATION OF THE DORSAL RAPHE
Our initial studies examined ISH autoradiograms to delineate
the organization of the DR and the neighboring 5-HT cell
groups in the human brainstem. Figure 1 illustrates a series
SERT autoradiograms from a representative control subject, with
images arranged from the anterior (Figure 1A) to the posterior
(Figure 1O) pole of the DR in 500µm increments between adja-
cent panels. At its anterior pole, the DR was barely noticeable
and was defined by loosely packed and scattered SERT signal
(Figures 1A–C); moving more posteriorly, the DR was defined
by fan-like shape with loosely packed horns located dorsolaterally
to its vertically oriented midline division (Figures 1D–F). At its
middle and middle-caudal levels (Figures 1G–L), the dorsolat-
eral horns narrowed and increased their density of hybridization
signal, and the overall shape of the DR resembled the letter V as
indicated by arrowheads in Figure 1K. At the more caudal lev-
els, the DR became loosely packed with ill-defined borders and
was contiguous with dispersed 5-HT cell groups located ventrally
(Figures 1M–O).
These rostro-caudal differences in the organization of the DR
correspond with functional and connectional differences (Abrams
et al., 2004; Lowry et al., 2008). Tract-tracing studies in ani-
mal models have demonstrated that the caudal portion of the
DR receives strong afferent inputs from several forebrain lim-
bic regions, including medial prefrontal cortex, habenula, and the
hypothalamus, while giving rise to projections to the hippocampus
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FIGURE 1 | Serotonin transporter (SERT) mRNA defines serotonergic
cell groups in the brainstem. Sections are arranged from anterior (A) to
posterior (O) pole of the raphe nuclei in 500µm intervals. Arrowheads in (K)
identify location of the dorsal raphe. Note differences in its shape, as well as
distribution and density of the signal within the: rostral (A–C), middle-rostral
(D–F), middle-caudal (G–L), and caudal (M–O) subdivisions of the dorsal
raphe (see text for additional details). LCM samples were collected from
the middle-caudal region of the dorsal raphe, panels (I–L). Sections were
processed for radioactive in situ hybridization using a riboprobe based on
NCBI nucleotide accession #NM 001045.2, pos. 705–1789.
and lateral septum (Wyss et al., 1979; Lee et al., 2003; Waselus
et al., 2006). Previous post-mortem human brain studies have also
demonstrated more robust gene expression differences within the
middle-caudal DR, as opposed to its more rostral subdivisions, in
depressed suicide individuals (Bach-Mizrachi et al., 2006, 2008).
Based on these observations we collected our samples from the
middle-caudal level of the DR (Figures 1I–L).
RNA QUALITY
Quality of extracted RNA was determined by analyzing electro-
pherograms obtained from 2100 BioAnalyzer. Previous work has
demonstrated that samples with ≤65% of their signal (quantified
by area under the curve) before the 18S rRNA peak and with≥4%
of the signal within the 28S rRNA peak are compatible with gene
expression profiling analyses (Schoor et al., 2003; Bernard et al.,
2009, 2011). In our control samples we observed 48.5± 3.27%
(mean± SEM; 95% CI: 46.0–50.9%) of signal <18S area of elec-
tropherogram, and 7.2± 1.5% (95% CI: 4.4–10.1%) within the
28S peak. In the MDD samples these measures were: 50.5± 1.6%
(95% CI: 48.9–52.1%) and 7.5± 0.7% (95% CI: 5.6–9.4), respec-
tively. Since group differences were not significant (p> 0.05) and
observed values were all well above inclusion thresholds, these
data indicate that extracted RNA was compatible with downstream
gene expression profiling and qPCR quantification.
OVERALL MICROARRAY RESULTS
Overall expression intensity for the microarray data from RMA
log2 values was 6.57± 0.01 in the C group and 6.58± 0.01
in the MDD group. Raw detection call rates calculated from
MAS5CALLS output were 49.0± 1.4% for the C group and
47.9± 1.5% for the MDD group. We found no significant dif-
ferences in RMA intensity values or MAS5CALLS detection call
rates (p> 0.05).
The average Pearson correlation among all of the samples was
0.95± 0.007. One of the samples (subject 3365) had an average
correlation of 0.83 with the other samples. However, removing this
sample from our analyses, did not significantly impact the largest
changes in gene expression that we detected (see Tables 3 and 4).
Heat map of differentially expressed genes included in functional
pathways analysis (see below) revealed a clear separation between
C and MDD samples (Figure 2).
FUNCTIONAL PATHWAYS
To evaluate differential expression we used the MAS5CALLS algo-
rithm, which computes through selective match/mismatch ratio,
the certainty with which a transcript is detected on a microarray
chip. Genes that had log2 RMA mean intensity values≥4.0, exhib-
ited MAS5CALLS detection call rates ≥50% in C or MDD group,
were upregulated or downregulated by ≥1.1-fold at p< 0.05 level
were included. Using these criteria, a total of 292 genes were
found to be differentially expressed between C and MDD sam-
ples, and of these, 126 genes were downregulated and 166 were
upregulated (see Supplementary Materials). We utilized Ingenu-
ity Pathway Analysis5 to identify functional pathways that are
impacted by these expression changes. A total of 21 cannoni-
cal pathways were identified as significantly involved (p< 0.05);
these pathways were grouped into 8 functional categories:n-glycan
biosynthesis, metabolism, axonal guidance signaling, mitochon-
drial dysfunction, intracellular signaling, transcription regulators,
NRF2-mediated oxidative stress response, and cell cycle regulation
(Table 3).
TRANSCRIPTION REGULATORS AND DOWNSTREAM TARGETS
As the next step, we used an unbiased analysis approach to detect
genes that exhibited the largest differences in expression between
C and MDD samples. Microarray data were filtered for genes
that were identified as detected by MAS5CALLS algorithm on
5http://www.ingenuity.com/products/pathways_analysis.html
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Table 3 | Functional groups that showed significant alterations in gene
expression.
N-glycan biosynthesis Intracellular signaling
B4GALT6 ↓ ANLN ↓
MAN2A1 ↓ PPP1R3C ↓
B4GALT2 ↑ ITPR1 ↓
DOLK ↑ GNG4 ↓
RPN1 ↑ GNA13 ↓
PRKAG2 ↓
Metabolism RDX ↓
ALDH1A1 ↓ SAT1 ↓
SDHC ↓ PIP4K2B ↑
BDH1 ↑ PARD6A ↑
DGKQ ↑ CDH2 ↑
LIPE ↑ TOLLIP ↑
VAMP2 ↑
Axonal guidance signaling NPR2 ↑
CXCR4 ↓
ARHGEF7 ↓ Transcription regulators
VEGFC ↓ EGR1 ↓
SEMA3G ↑ TOB1 ↓
KLC1 ↑ NR4A2 ↓
RND1 ↑ NR4A3 ↓
ARPC1B ↑ SMAD6 ↑
LINGOl ↑
PIK3CD ↑ NRF2-mediated oxidative stress response
MAFF ↓
Mitochondrial dysfunction AKR7A2 ↑
F1S1 ↑ GSTT1 ↑
NDUFB3 ↑ VCP ↑
COX6A1 ↑ CYP4Z1 ↑
PRDX5 ↑ CDC34 ↑
PSEN2 ↑
Cell cycle regulation
HNRNPA1 ↓
CCNE2 ↓
CCND2 ↓.
TINF2 ↑
MAX ↑
Using Ingenuity Pathway Analysis we identified a total of 21 canonical pathways
that exhibited significant alterations in expression (p<0.05). These pathways
belonged to eight distinct functional groups (bold headings); within each func-
tional group genes that were significantly altered in the MDD group as compared
to the C group are listed with arrows indicating upregulation or downregulation in
expression. Bold italics indicate genes that were among those that showed the
largest changes in expression (seeTable 4).
at least 50% of arrays in either group, had log2 RMA mean
intensity values≥4.0, and showed≥1.4-fold changes in expression
at p< 0.05. This approach revealed alterations in the expression
of 16 transcripts in MDD versus C. Expression of 13 of these
genes was downregulated, including: TOB1, NR4A2, EGR1, CD69,
TIPARP, ADM, PPP1R3C, CXCR7, NR4A3, SLC19A2, EEF1A1,
CCDC58, and SYTL4 (Table 4). Expression of two genes, GSTT1
and PYROXD1, was upregulated, while that of a non-protein
coding RNA CHST9-AS1 was downregulated in the MDD group
(Table 4).
Examination of the top genes within the framework of pathway
analysis revealed that three functional groups – (1) Intracellular
Signaling, (2) Transcription Regulators, and (3) NRF2-Mediated
Oxidative Stress Response, contained genes with the largest
(≥1.40-fold change) changes in expression. Of these, the Tran-
scription Regulators functional group contained the greatest num-
ber of such genes, which included: EGR1, TOB1, NR4A2, and
NR4A3 (Tables 3 and 4).
Confirmation of expression changes by qPCR was conducted
on samples from all subjects and included 11 transcripts. The
changes in expression detected by both microarrays and by qPCR
were always in the same direction (Table 4). We observed a signif-
icant (p< 0.05) correlation between microarray and qPCR results
for all genes, with the exception of NR4A3 (Table 4). Changes in
the expression of five transcripts (TOB1, NR4A2, EGR1, TIPARP,
and ADM) reached statistical significance (p≤ 0.05) as detected
by qPCR, whereas changes in the expression of three other
genes (CD69, PPP1R3C, and CXCR7) exhibited a trend toward
significance (p≤ 0.1; Table 4).
Using IPA functional networks feature, we extended our analy-
sis to downstream targets of TOB1, NR4A2, and EGR1. Genes
were included in this analysis if they were detected in ≥50% of C
or MDD microarrays and were altered in their expression by 1.1-
fold or greater at the level of p< 0.05. In the case of TOB1, this
analysis revealed a downregulation of SMAD2-SMAD4-TOB and
SMAD3-SMAD4-TOB transcriptional regulation complexes along
with the downregulation of CCNE2, a cell cycle regulator that
belongs to the Cyclin E complex (Figure 3). Expression of mul-
tiple genes was downregulated downstream of EGR1, including
that of: CCND2, CSDA (which has a reciprocal relationship with
EGR1), GADD45B, PPP1R3C, and THRB. Additionally, expres-
sion of CHGA, THRA, ALOX5, and CDKN1C was upregulated
downstream from EGR1. In the case of NR4A2, its downstream
targets of ADM and NR4A3 were downregulated, while CDKN1C
and SLC6A3 were upregulated. Interestingly, NR4A3 exhibits a
reciprocal relationship with NR4A2, while CDKN1C expression is
regulated by both NR4A2 and EGR1 (Figure 3).
To determine the pattern of expression within the DR of EGR1,
NR4A2,and ADM (a downstream target of NR4A2),we performed
ISH in three of the control subjects on tissue sections that con-
tained the middle-caudal DR (Figure 4). These genes were widely
expressed at relatively low levels, as is true of other transcriptional
regulators (Kerman et al.,2012). These ISH data suggest that EGR1,
NR4A2, and ADM are expressed within a variety of cell types, but
are enriched in their expression within the DR (Figure 4). Based
on this hybridization pattern, it is likely that these genes impact a
wide variety of cellular functions and neuronal circuits.
IMPACT OF MEDICATION
To assess potential medication effects, we examined expression
levels of EGR1, TOB1, NR4A2, and ADM in MDD patients who
were prescribed SSRIs at the time of death (MDD+ SSRI) and
in those who were not (MDD−). Because microarrays and qPCR
are complementary measures of gene expression we used a meta-
analytic approach of z-score normalization to combine microarray
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Table 4 | Results of microarray and qPCR experiments.
Ref seq ID Gene name Symbol Gene expression Microarray qPCR Array-qPCR
Log 2 mean
intensity
p-Value F -change p-Value F -change p-Value r
Genes (log2 intensity>4; p<0.05; fold-change>1.4)
NM_005749 Transducer of ERBB2, 1 TOB1 10.1 0.034 −1.95 0.021 −1.67 <0.0001 0.90
NM_173173 Nuclear receptor subfamily 4, group A,
member 2
NR4A2 6.3 0.007 −1.87 0.032 −3.57 <0.01 0.63
NM_001964 Early growth response 1 EGR1 8.8 0.023 −1.71 0.046 −2.96 <0.01 0.59
NM_001781 CD69 molecule CD69 5.3 0.036 −1.72 0.076 −2.68 <0.05 0.51
NM_015508 TCDD-inducible poly(ADP−ribose)
polymerase
TIPARP 9.0 0.012 −1.60 0.038 −2.26 <0.0001 0.93
NM_001124 Adrenomedullin ADM 9.3 0.008 −1.59 0.025 −2.81 <0.0001 0.70
NM_005398 Protein phosphatase 1, regulatory
(inhibitor) subunit 3C
PPP1R3C 8.9 0.010 −1.59 0.061 −2.03 <0.0001 0.95
NM_020311 CXCR7 chemokine (C−X−C motif)
receptor 7
CXCR7 8.7 0.049 −1.57 0.098 −1.67 <0.0001 0.90
NM_173199 Nuclear receptor subfamily 4, group A,
member 3 (NR4A3)
NR4A3 5.6 0.001 −1.54 0.127 −1.51 0.46 0.17
NM_006996 Solute carrier family 19 (thiamine
transporter), member 2
SLC19A2 7.0 0.041 −1.53 0.125 −1.58 <0.0001 0.87
NM_001402 Eukaryotic translation elongation factor
1 alpha 1
EEF1A1 8.4 0.016 −1.42 0.117 −2.36 <0.0001 0.58
NM_001017928 Coiled-coil domain containing 58 CCDC58 5.5 0.003 −1.48
NM 080737 Svnaptotagmin-like 4 SYTL4 6.3 0.043 −1.49
NM_153010 CHST9 antisense RNA 1 (non-protein
coding)
CHST9-AS1 6.7 0.017 −1.59
NM_024854 Pyridine nucleotide-disulphide
oxidoreductase domain 1
PYROXD1 9.6 0.022 1.56
NM 000853 Glutathione S-transferase theta 1 GSTT1 5.6 0.014 1.43
F-change indicates fold change in the MDD group as compared to the C group. Significant (p<0.05) changes are indicated in bold; those that exhibited a trend toward
significance (p<0.1) are italicized. Correlations between microarray and qPCR results are also presented; r, Pearson’s r correlation coefficient.
and qPCR results (Jain et al., 2005; Guilloux et al., 2011). Individual
z-scores were calculated by normalizing differences between each
data point and the mean of the C group to the standard deviation
of the C group. Within subject microarray and qPCR z-scores were
averaged for each gene, and this average z-score was then used for
group comparisons. This analysis revealed significant (p< 0.05)
downregulation in the expression of TOB1, NR4A2, and ADM
in MDD-subjects, and a trend (p< 0.1) for downregulation for
EGR1, as compared to C subjects (Figure 5). In the MDD+ SSRI
group, we observed significant (p< 0.05) downregulation in the
expression of ADM, and a trend for downregulation in EGR1
(p= 0.1) and NR4A2 (p= 0.1), as compared to the C group.
DISCUSSION
This study examined DR in post-mortem brains from patients
diagnosed with MDD and from psychiatrically normal compari-
son subjects. We utilized the ISH-guided LCM approach to collect
DR samples, because our previous studies validated this approach
in gene expression studies in postmortem human brain tissue
(Bernard et al., 2009, 2011). This method combines a high level
of anatomical resolution with more precise tissue sampling, which
enriches specific mRNAs and improves sensitivity and the dynamic
range of microarray-based gene expression profiling (Bernard
et al., 2009). We also chose to look at the entire region of DR
within each section rather than capturing individual neurons,
because previous studies indicate the importance of the entire
cellular milieu of the DR, including neurons of different neuro-
chemical content (i.e., 5-HT and non-5-HT containing; Lemos
et al., 2006). Other studies have also highlighted the importance
of glia and glial-neuronal interaction in normal brain function,
as well as in MDD, in multiple cortical and subcortical brain
regions (Rajkowska and Miguel-Hidalgo, 2007; Bernard et al.,
2011; Parpura et al., 2012). Our microarray data suggest that
a number of functional gene networks are altered in the DR
in the MDD brain. These include: biosynthesis and metabo-
lism, axonal guidance, mitochondrial dysfunction and oxidative
stress, cell cycle regulation, and intracellular signaling and tran-
scriptional regulation. Of these functional groups, genes with the
largest changes in expression belonged to the transcriptional reg-
ulation group, and subsequent qPCR validation confirmed the
downregulation in the expression of EGR1, TOB1, and NR4A2.
These changes did not appear to be due to medication effects, and
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FIGURE 2 | Heatmap of differentially expressed genes included in
functional pathways analysis (see text for more details). It was
generated by using the method of King et al. (2005) and publicly available
software at http://ashleylab.stanford.edu/tools_scripts.html.
functional pathway analysis of the microarray data revealed alter-
ations in the expression of several downstream targets of these
transcriptional regulators. Our preliminary anatomical studies
suggest that EGR1 and NR4A2, as well as ADM (a downstream
target of NR4A2 that was also significantly downregulated in
MDD), are widely expressed, but are enriched in their expres-
sion within the DR. These observations suggest transcriptional
alterations within multiple cell types in the DR, which may have
diverse functional consequences on its function.
LIMITATIONS
As in all post-mortem human brain investigations, our study has
several methodological limitations. Most importantly, one needs
to be aware that our observations are correlational, and thus we
cannot know from our data whether these molecular alterations
contribute to the emergence of MDD or are its consequence.
Nonetheless, our data are consistent with other studies that have
implicated EGR1, NR4A2, and TOB1 in a number of functional
processes that are dysregulated in neuropsychiatric disorders (see
below).
We focused on gene expression at the middle-caudal portion
of the DR, because 5-HT neurons within the rostral DR are more
likely to project to motor targets, while those located more cau-
dally are enriched in their projections to the forebrain limbic
targets, including hippocampus and lateral septum (Wyss et al.,
1979; Waselus et al., 2006). These limbic nuclei play an impor-
tant role in reward and memory function, which are impaired in
MDD. Previous post-mortem studies also reported gene expres-
sion alterations in the DR of depressed suicides, with the largest
differences within its middle-caudal portion (Bach-Mizrachi et al.,
2006, 2008). Taken together, these studies suggest that the middle-
caudal DR plays an important role in affective regulation and is
specifically impacted in MDD. Future work will be required to
determine whether gene expression changes that we observed in
this DR subregion extend to its more rostral subdivisions.
Subjects included in our study were severely depressed at the
time of death. Nearly half of them committed suicide, which
was likely related to their depression. Therefore, it may be that
our observed gene expression changes are not present in mildly
or moderately depressed individuals. In addition, in most post-
mortem studies of neuropsychiatric diseases it is very difficult to
determine whether observed effects are due to the illness itself, or
due to the medications used to treat the disease. To address this
issue we parsed MDD subjects into those who were and into those
who were not prescribed SSRIs at the time of death. This analy-
sis demonstrated significant downregulation in the expression of
TOB1, NR4A2, and ADM, and a trend toward significance for
EGR1, in the latter group relative to the controls. Though we can-
not rule out potential impact of other drugs, these results suggest
that our observations are not due to SSRIs, the most common med-
ications used to treat MDD. Nonetheless, the observed alterations
in gene expression need to be replicated in an independent cohort
of subjects to increase confidence in our results.
We designed the present study to examine gene expression alter-
ations within the entire cellular milieu of the middle-caudal DR.
The advantage of this approach is that we were able to: (1) tar-
get the portion of the DR that regulates limbic functions, (2)
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FIGURE 3 | Downstream gene targets ofTOB1, EGR1, and NR4A2 that
were altered in their expression in the MDD group as compared to the C
group. Genes were included in this analysis if: (1) they were detected in
≥50% of arrays in either the MDD or C group, (2) their changes in expression
were ≥1.1- or ≤−1.1-fold in magnitude, and (3) associated p-values<0.05.
Gene-gene interactions were analyzed using Ingenuity Pathway Analysis
knowledge database. Marked in red are gene products that were upregulated,
while those in green were downregulated.
examine gene expression alterations within multiple cell types,
and (3) identify functional pathways most strongly impacted by
MDD. However, the drawback of this approach is that it lacks cellu-
lar resolution and we cannot know whether these gene expression
changes impact a variety of cell types within the DR, or if they
are restricted to a particular functional class. Future studies that
utilize single cell analyses will be required to address this issue.
FUNCTIONAL PATHWAYS ALTERATIONS
Pathway analysis of the microarray data revealed dysregulation
in the DR of MDD patients within several functional gene
groups, including those that regulate: biosynthesis, metabolism,
axon guidance, mitochondrial function, intracellular signaling,
transcription, oxidative stress response, and the cell cycle. These
data suggest that a defined set of cellular functions are dysregulated
in the DR in MDD, including: (1) intracellular stress and energy
balance, (2) intracellular signaling and transcriptional regulation,
and (3) cell proliferation and connectivity.
Previous studies have implicated these, or related, functional
groups in the pathophysiology of mood disorders in other brain
regions. For example, decreased cell proliferation may contribute
to the decrease in the numbers of glial cells and glial markers
within cortical and subcortical brain regions in the depressed brain
(Rajkowska, 2003; Rajkowska and Miguel-Hidalgo, 2007; Bernard
et al., 2011). Likewise, increased hippocampal neurogenesis has
been proposed to underlie the mechanism of antidepressant
action (Perera et al., 2007; Boldrini et al., 2009). Alterations in
the expression of cell connectivity markers are consistent with
imaging reports demonstrating alterations in resting-state con-
nectivity among several limbic brain regions in MDD (Fingelkurts
et al., 2007; Greicius et al., 2007). Mitochondrial dysfunction and
impaired intracellular stress response have also been implicated
in the emergence of bipolar disorder and depression (Rezin et al.,
2009). Taken together with our data, these observations suggest
that MDD is associated with the dysregulation of a set of func-
tional pathways across multiple brain regions. Future work will
be required to determine how these alterations impact specific
cell types and circuits, and how these functional changes mediate
clinical manifestations of mood disorders.
TRANSCRIPTIONAL DYSREGULATION IN THE DR
Cellular transcription is a process that is tightly controlled by
DNA-binding factors that regulate a variety of process, such as
neurodevelopment, adaption to environmental cues, intracellular
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FIGURE 4 | In situ hybridizations for EGR1, ADM, and NR4A2. Tissue
was processed for radioactive ISHs as previously described
(Lopez-Figueroa et al., 2004; Bernard et al., 2009), using the following
probes: EGR1, accession # NM_001964, pos. 857–1495; ADM, accession #
NM_001124, pos. 701–1349; NR4A2, accession # NM_NM 173173, pos.
344–669. Binding with antisense (left column) and sense (right column)
riboprobes is illustrated to compare specific and non-specific binding.
Arrows indicate location of the dorsal raphe; compare to signal in
Figures 1I–L. Note the presence of specific signal that is enriched within
the DR in the antisense images, but is absent in the sense ones.
signaling, cell cycle control, and others (Collins et al., 1995; Cho
et al., 2001; Lonze and Ginty, 2002). Thus, in the intracellular sig-
naling chain, transcriptional regulators are at the cusp between the
effects of an external stimulus and its impact on cellular function.
Altered transcriptional control can result in dysregulated expres-
sion of a host of downstream genes, and such changes have been
observed in cancer, autoimmune diseases, diabetes as well as in
neuropsychiatric disorders (Abraham and Kroeger, 1999; Black
et al., 2001; Habener et al., 2005; Monteggia and Kavalali, 2009;
Robison and Nestler, 2011). Many of these studies report global
transcriptional alterations, but local circuitries may contain yet
undetected defects in transcriptional control. Indeed, upregula-
tion in the expression of NUDR and REST, both of which are 5-
HT-related transcriptional regulators, have been recently reported
within serotonergic neurons in the DR (Goswami et al., 2010).
Interestingly, these changes were sex-dependent and were only
apparent in female subjects. Here we report that among the DR
transcripts that exhibited the most significant and largest expres-
sion differences in MDD, there are three transcription factors:
TOB1, NR4A2, and EGR1.
Because these genes are transcriptional regulators, we used
functional pathway analysis to identify changes in expression of
their downstream targets. This approach revealed alterations in
the expression of several downstream targets in our microarray
data set. These included other transcriptional regulators: NR4A3,
THRA, THRB, and CSDA. In addition to these direct transcrip-
tional regulators, we also observed a downregulation in the expres-
sion of GADD45B, a downstream target of EGR1 and an epigenetic
regulator that mediates activity-dependent DNA demethylation
(Ma et al., 2009). These observations suggest alterations in tran-
scriptional regulation via changes in the expression of factors that
bind directly to the genome,as well as those that mediate epigenetic
regulation of gene expression.
Analysis of downstream targets also revealed downregulation
in the expression of CCND2 and CCNE2, downstream targets
of EGR1 and TOB1, respectively. Both of these genes are part
of the cell cycle regulation group, which we observed as signifi-
cantly altered using functional pathway analysis (Table 3). We also
detected a downregulation in the expression of PPP1R3C, down-
stream of EGR1, and that of ADM, downstream of NR4A2, both
of which were among the genes that showed that largest changes
in expression (Table 4). ADM is a widely expressed peptide that
exerts its actions via a G protein coupled receptor, which when
activated triggers a second messenger cascade that regulates gene
transcription (Cuttitta et al., 2002). Altered expression of ADM has
been previously correlated with mood disorders, while its knock-
out in mice leads to heightened anxiety-like behavior (Savas et al.,
2002; Fernandez et al., 2008; Huang et al., 2010). In addition, a
recent study has identified NR4A2 as a regulator of EGR1 expres-
sion, raising the possibility that these transcriptional regulators
also directly interact with each other (Johnson et al., 2011).
Previous studies have implicated alterations in the expression or
function of EGR1, NR4A2, and TOB1 in brain processes impacted
by MDD. For example, TOB1 expression is altered in the frontal
cortex of patients with bipolar disorder (Bezchlibnyk et al., 2001),
while molecular interference with the TOB1 protein suppresses
long-term potentiation and impairs spatial learning and mem-
ory in rats (Jin et al., 2005). Previous work has demonstrated
that TOB-interacting proteins play a role in neuronal differen-
tiation, suggesting that TOB1 is expressed in neurons (Berthet
et al., 2002). TOB1 plays a fundamental role in cell proliferation
and growth (Maekawa et al., 2002), and it is feasible that its dys-
function may lead to morphological changes observed in the DR
of MDD patients (Baumann et al., 2002).
Studies focused on NR4A2 have demonstrated its importance
in the genesis of dopaminergic neurons (Ojeda et al., 2003; Gal-
leguillos et al., 2010). In addition to the decrease in NR4A2
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FIGURE 5 | Effect of SSRI treatment on gene expression. Within subject
microarray and qPCR z -scores were combined for each gene: EGR1 (A),
TOB1 (B), NR4A2 (C), and ADM (D). Data are shown as Mean±SEM
z -scores for: Contol subjects (n=8), MDD subjects not treated with SSRIs
(MDD−; n=8) at the time of death, and MDD subjects treated with SSRIs
(MDD+SSRI; n=5) at the time of death (see text for more details).
expression, functional pathway analysis of our data also revealed
an upregulation in the expression of the dopamine transporter
(SLC6A3; Figure 3). DR contains a large number of catecholamin-
ergic neurons that give rise to ascending projections to nucleus
accumbens, prefrontal cortex, and the lateral septum, key areas
in the regulation of affect and reward (Stratford and Wirtshafter,
1990; Michelsen et al., 2007). Taken together, these observations
suggest that functional alterations of ascending catecholamine
circuits from the DR may contribute to the etiology of MDD. Con-
sistent with this notion is the observation that mice with reduced
NRA2 exhibit alterations in forebrain levels of dopamine and 5-
HT along with increased immobility on the forced swim test, a
measure of learned helplessness and a core feature of MDD (Rojas
et al., 2010).
EGR1 is a transcriptional switch that regulates a number of
diverse gene targets. It is an immediate-early gene that gets acti-
vated in response to a variety of stimuli, including drug adminis-
tration that leads to 5-HT release (Humblot et al., 1998). Previous
work indicates that it is strongly expressed in neurons in the adult
brain, and that its levels are altered by neurotransmitter release
and neuronal activation (Knapska and Kaczmarek, 2004). It can
also exert long-lasting changes in gene expression and subsequent
protein synthesis that mediate synaptic plasticity. EGR1 has been
implicated in mediating a variety of behaviors that are dysregu-
lated in MDD, including learning and memory, fear conditioning,
drug addiction, and social interaction (Cole et al., 1989; Ressler
et al., 2002; Malkani et al., 2004; Valjent et al., 2006; Stack et al.,
2010). Extensive evidence also implicates 5-HT signaling in medi-
ating neuroplasticity, such as functional plasticity in the cortex
following sensory deprivation (Maya Vetencourt et al., 2008; Jit-
suki et al., 2011). These observations raise the possibility that
altered EGR1 expression in the DR may lead to disruption of
5-HT-mediated plasticity within the limbic forebrain regions.
A recent report has documented a decrease in the cross-
sectional area of the DR in MDD (Matthews and Harrison, 2012).
This observation may be due to a variety of factors, including
decreased numbers of neurons or glia, or decreased density of
synaptic inputs or diminished dendritic branching of DR neurons.
Given that TOB1 and NRA2 play an important role in neuronal
differentiation, it is feasible that alterations in their expression may
contribute to morphological alterations within the DR associated
with MDD.
CONCLUSION
Transcriptional regulators mediate a number of brain functions
and behaviors that are dysregulated in MDD, including learning
and memory, fear consolidation, and cognitive function (Morris
et al., 1988; Ressler et al., 2002; Malkani et al., 2004). Transcrip-
tional dysregulation has also been previously implicated in the eti-
ology of diverse neuropsychiatric disorders such as Rett syndrome,
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addiction, schizophrenia, bipolar disorder, and MDD (Law et al.,
2006; Monteggia and Kavalali, 2009; Goswami et al., 2010; Soria
et al., 2010; Robison and Nestler, 2011). Because of its key role
in central 5-HT neurotransmission and extensive evidence for its
functional and structural alterations in mood disorders, along with
similar alterations in rodent models of depression, the DR likely
plays a key role in the pathophysiology of MDD. Our data point
to the dysregulation of multiple transcriptional regulators in the
DR, including: (1) transcription factors that directly bind to the
genome in response to upstream gene activation or environmental
cues (i.e., EGR1, TOB1, and CSDA), (2) ligand-activated nuclear
receptors that regulate transcription via their genomic actions
(NR4A2, NR4A3, THRA and THRB), (3) an epigenetic regula-
tor (GAAD45B), and (4) a peptide that regulates transcription
via its binding to a G protein coupled receptor and downstream
activation of intracellular signaling (ADM). These observations
suggest alterations in the function of a host of downstream targets,
which may lead to the dysregulation of multiple cellular functions
that contribute to the pathophysiology of MDD. Future studies
will require single cell analyses in the DR to determine potential
impact of these changes on its cellular functions and related cir-
cuits. One approach would be to use data from previous studies
that used microarrays to fingerprint individual classes of cells in
the brain (Ponomarev et al., 2006). However, since such data are
not available for the human brainstem, studies utilizing single cell
LCM in the postmortem human brain will be required (Goswami
et al., 2010; Ordway et al., 2012).
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